Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences 3D-Bioprinting "Track B"

Paul Gatenholm's Biography

Paul Gatenholm, Professor, Director of 3D Bioprinting Center, Chalmers University of Technology, Sweden; CEO, CELLHEAL AS, Norway

Dr. Gatenholm is professor of Biopolymer Technology at Chalmers University of Technology, Founder of 3D Bioprinting Center, and Director of Graduate School at WWSC. He is also Adjunct Professor at Joint School of Biomedical Engineering and Sciences at Virginia Tech and Wake Forest University and Adjunct Professor of Biomaterials at Wake Forest Institute for Regenerative Medicine in Winston-Salem, North Carolina, USA. His research includes biological fabrication through the use of enzymes, cells, and the coordination of biological systems. Dr. Gatenholm is particularly interested in designing and preparing new biomaterials which can replace or regenerate tissue and organs. During past five years he has dedicated his time to development of 3D Bioprinting technology which he believes will revolutionize the field of Medicine. He has published more than 300 papers and edited several books and has more than 9000 citations. He is elected member of Swedish Royal Academy of Engineering Sciences. Dr Gatenholm is an entrepreneur and is currently CEO of new biotech start up in Oslo, Norway.

Paul Gatenholm Image

3D Bioprinting of Soft Tissue: Translation to Clinic

Thursday, 4 October 2018 at 10:00

Add to Calendar ▼2018-10-04 10:00:002018-10-04 11:00:00Europe/London3D Bioprinting of Soft Tissue: Translation to

3D Bioprinting has a potential to revolutionize regenerative medicine due to unique ability to place multiple cell types in predetermined position and build bottom up the microenvironment to control cellular fate processes. Adult stem cells can be harvested in operating room and combined with biopolymeric hydrogels and 3D bioprinted into desire shape. We have focused our research onto translation of 3D bioprinting technology to clinic. Together with plastic surgeons we are studying preclinical transplantation of 3D bioprinted constructs with stem cells isolated from patient in operating room. The goal is to promote wound healing and repair soft tissue. Translation includes regulatory approved cell isolation protocols and use of regulatory compliant bioinks. We have invented cell-instructive bioinks to be able to control cellular fate processes and to grow vascularized tissue which is of great interest for bringing 3D Bioprinting technology to clinic and space applications.

Add to Calendar ▼2018-10-04 00:00:002018-10-05 00:00:00Europe/London3D-Bioprinting "Track B"